• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

帕金森病发病率:规模、可比性、时间趋势。

Parkinson's disease incidence: magnitude, comparability, time trends.

作者信息

de Pedro-Cuesta J, Stawiarz L

机构信息

Unit for Neuroepidemiology and Health Services Research, Huddinge Hospital, Karolinska Institute, Sweden.

出版信息

Acta Neurol Scand. 1991 Nov;84(5):382-8. doi: 10.1111/j.1600-0404.1991.tb04974.x.

DOI:10.1111/j.1600-0404.1991.tb04974.x
PMID:1776385
Abstract

In this study, we reviewed incidence surveys of Parkinson's Disease (PD) from all over the world, published during the period 1945-1989, using reported quality criteria. In addition, we compared age-specific PD incidences from selected observations by stratified analysis. Crude incidences were described for 11 populations, and age-specific incidences for three of them: Iceland, Rochester (Minn, USA), and Turku (Finland). Effect modification by age was detected: a) by comparing incidences by age at diagnosis with incidence by age at clinical disease onset; and b) when only data on onset of disease was computed. For disease onsets, the incidences in Rochester for the period 1955-1966, and in Turku (Finland) during the interval 1968-1970, were lower than that in Iceland for the period 1958-1960: RR = 0.58 95% CI (0.41, 0.83), and RR = 0.67 95% CI (0.51, 0.87), respectively. For the Rochester population aged 40-69 years, a statistically significant 56% decrease in the incidences of Parkinsonism onsets during the period 1945-1966 was found. Validity problems in comparing PD incidences and the role of PD underdiagnosis were emphasized. We concluded that: a) stratified analysis is more suitable than standardization when comparing incidences for etiological purposes; b) the incidence of PD was highest in Iceland; and c) in Rochester, PD incidence under the age of 70 decreased with time.

摘要

在本研究中,我们使用报告的质量标准,回顾了1945年至1989年期间发表的来自世界各地的帕金森病(PD)发病率调查。此外,我们通过分层分析比较了选定观察对象的年龄特异性PD发病率。描述了11个人群的粗发病率,以及其中三个人群的年龄特异性发病率:冰岛、罗切斯特(美国明尼苏达州)和图尔库(芬兰)。检测到年龄对效应的修饰作用:a)通过比较诊断时年龄的发病率与临床疾病发病时年龄的发病率;b)仅计算疾病发病数据时。对于疾病发病情况,1955年至1966年期间罗切斯特的发病率,以及1968年至1970年期间图尔库(芬兰)的发病率,低于1958年至1960年期间冰岛的发病率:相对危险度(RR)分别为0.58,95%可信区间(CI)(0.41,0.83),以及RR = 0.67,95%CI(0.51,0.87)。对于40至69岁的罗切斯特人群,发现在1945年至1966年期间帕金森病发病的发病率有统计学意义的56%下降。强调了比较PD发病率时的有效性问题以及PD诊断不足的作用。我们得出结论:a)出于病因学目的比较发病率时,分层分析比标准化更合适;b)冰岛的PD发病率最高;c)在罗切斯特,70岁以下的PD发病率随时间下降。

相似文献

1
Parkinson's disease incidence: magnitude, comparability, time trends.帕金森病发病率:规模、可比性、时间趋势。
Acta Neurol Scand. 1991 Nov;84(5):382-8. doi: 10.1111/j.1600-0404.1991.tb04974.x.
2
Evaluation of how age modifies the risk for Parkinson's disease, based on stratified comparisons of descriptive data.基于描述性数据的分层比较,评估年龄如何改变帕金森病的风险。
Acta Neurol Scand. 1991 Oct;84(4):295-302. doi: 10.1111/j.1600-0404.1991.tb04958.x.
3
Time Trends in the Incidence of Parkinson Disease.帕金森病发病率的时间趋势。
JAMA Neurol. 2016 Aug 1;73(8):981-9. doi: 10.1001/jamaneurol.2016.0947.
4
Parkinson's disease occurrence in Europe.帕金森病在欧洲的发病情况。
Acta Neurol Scand. 1991 Oct;84(4):357-65. doi: 10.1111/j.1600-0404.1991.tb04969.x.
5
Incidence of Parkinson's disease and parkinsonism in northern Sweden: a population-based study.瑞典北部帕金森病和帕金森综合征的发病率:一项基于人群的研究。
Mov Disord. 2010 Feb 15;25(3):341-8. doi: 10.1002/mds.22987.
6
High levodopa use in periodically time-clustered, Icelandic birth cohorts. A vestige of parkinsonism etiology? Europarkinson Preparatory Activity Research Group.冰岛出生队列中左旋多巴在特定时间聚集期的高剂量使用。帕金森病病因的一种残留现象?欧洲帕金森病前期活动研究小组
Acta Neurol Scand. 1995 Feb;91(2):79-88. doi: 10.1111/j.1600-0404.1995.tb00412.x.
7
Influence of strict, intermediate, and broad diagnostic criteria on the age- and sex-specific incidence of Parkinson's disease.严格、中等和宽泛诊断标准对帕金森病年龄和性别特异性发病率的影响。
Mov Disord. 2000 Sep;15(5):819-25. doi: 10.1002/1531-8257(200009)15:5<819::aid-mds1009>3.0.co;2-p.
8
Prevalence of Parkinson's disease in Junín, Buenos Aires Province, Argentina.阿根廷布宜诺斯艾利斯省胡宁地区帕金森病的患病率。
Mov Disord. 1997 Mar;12(2):197-205. doi: 10.1002/mds.870120210.
9
Parkinson disease with and without Dementia: A prevalence study and future projections.帕金森病伴或不伴痴呆:一项患病率研究及未来预测。
Mov Disord. 2018 Apr;33(4):537-543. doi: 10.1002/mds.27277. Epub 2018 Jan 22.
10
Systematic review of incidence studies of Parkinson's disease.帕金森病发病率研究的系统评价
Mov Disord. 2003 Jan;18(1):19-31. doi: 10.1002/mds.10305.

引用本文的文献

1
Declining incidence of Parkinson's disease in Israel (2002-2021).以色列帕金森病发病率下降(2002 - 2021年)。
J Neural Transm (Vienna). 2025 Jul 22. doi: 10.1007/s00702-025-02984-2.
2
Seasonality as a risk factor for deaths in Parkinson's disease.季节变化作为帕金森病死亡的一个风险因素。
Clinics (Sao Paulo). 2024 Oct 25;79:100506. doi: 10.1016/j.clinsp.2024.100506. eCollection 2024.
3
Circadian re-set repairs long-COVID in a prodromal Parkinson's parallel: a case series.昼夜节律重置修复长新冠与前驱帕金森平行:一项病例系列研究。
J Med Case Rep. 2024 Oct 23;18(1):496. doi: 10.1186/s13256-024-04812-9.
4
Polychromatic Light Exposure as a Therapeutic in the Treatment and Management of Parkinson's Disease: A Controlled Exploratory Trial.多色光照射作为帕金森病治疗与管理的一种疗法:一项对照探索性试验。
Front Neurol. 2018 Sep 19;9:741. doi: 10.3389/fneur.2018.00741. eCollection 2018.
5
Circadian Dysregulation in Parkinson's Disease.帕金森病中的昼夜节律失调
Neurobiol Sleep Circadian Rhythms. 2017 Jan;2:53-58. doi: 10.1016/j.nbscr.2016.11.001. Epub 2016 Nov 12.
6
Alteration of daily and circadian rhythms following dopamine depletion in MPTP treated non-human primates.MPTP 处理的非人灵长类动物多巴胺耗竭后昼夜节律的改变。
PLoS One. 2014 Jan 23;9(1):e86240. doi: 10.1371/journal.pone.0086240. eCollection 2014.
7
Cost effectiveness of treatment of Parkinson's disease with entacapone in the United States.在美国,恩他卡朋治疗帕金森病的成本效益。
Pharmacoeconomics. 2002;20(9):617-28. doi: 10.2165/00019053-200220090-00005.
8
Selegiline: an appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in Parkinson's disease.司来吉兰:对其在帕金森病中药物经济学和生活质量益处依据的评估
Pharmacoeconomics. 1992 Aug;2(2):118-36. doi: 10.2165/00019053-199202020-00005.